Viscosupplementation Market, Global Forecast Report by Injections (Single, Three and Five), Application (Knee, Hip, Hand/Wrist, Ankle/Foot, and Others), End User (Hospitals, Orthopedic Clinics/Ambulatory Surgical Centres), Regions and Company Analysis 2025-2033

The main application of viscosupplementation is in the treatment of osteoarthritis, where the synovial fluid of the joint, which normally acts as a cushion and lubricant, becomes thinner and less effective due to inflammation and cartilage breakdown. Hyaluronic acid injection in the process of viscosupplementation helps improve joint lubrication, reduces friction, and alleviates pain. Viscosupplementation is usually recommended for patients who have not found relief through oral medications or physical therapy. It is considered a minimally invasive procedure with fewer side effects compared to surgery, making it an attractive option for managing chronic joint pain. In addition to knee osteoarthritis, viscosupplementation can be used for other joints like the hip and shoulder, offering a non-surgical solution for joint health management.

Growth Driver in the Viscosupplementation Market

Increasing Prevalence of Osteoarthritis

The growing incidence of osteoarthritis, especially among the elderly, is a major factor driving the viscosupplementation market. Osteoarthritis is a common cause of joint pain and disability, especially in weight-bearing joints such as the knees. As the global population ages, demand for non-invasive treatments like viscosupplementation to manage OA symptoms increases. With fewer side effects and less risk compared to surgery, viscosupplementation is a very effective pain relief treatment and is more preferred by most patients who suffer from joint degeneration.

Increasing Popularity of Minimally Invasive Treatments

Health care is increasingly turning towards minimal invasive procedures, and so is the popularity of viscosupplementation for treating joint pain. Unlike other surgical treatments, viscosupplementation requires simple injections with minimal recovery time, and this reduces patient downtime and healthcare costs. This appeal is powerful among patients seeking to avoid surgery due to risks, long recovery times, or personal preference. The growing focus on reducing hospital stays and recovery time has further boosted the demand for injectable therapies like viscosupplementation, driving market growth.

Advancements in Hyaluronic Acid Formulations

Recent advancements in the formulation of hyaluronic acid (HA) used in viscosupplementation have improved the treatment's effectiveness and longevity. Such improvements have enabled products of HA to come up with longer-acting relief with fewer injections, hence increasing compliance and satisfaction of the patients. These innovations make viscosupplementation a more acceptable alternative than traditional treatments like oral medication or physical therapy. Improvement in the quality of HA and the products that suit the level of osteoarthritis make the market adopt and grow.

Challenges in the Viscosupplementation Market

High Treatment Costs

One of the significant challenges in the viscosupplementation market is the high cost of treatment, particularly in countries where insurance coverage may only partially reimburse the procedure. The cost of viscosupplementation injections can be a barrier for many patients, especially when multiple injections are required over time. These high prices ensure the treatment is out of the reach of people not well covered by insurance, much less those in more poorly paying demographics. The regional acceptance of viscosupplementation may therefore be delayed, which will reduce its market growth.

Lack of Awareness and Adoption

While viscosupplementation works, there remains little education and knowledge regarding treatment for both healthcare professionals and patients. Many patients diagnosed with osteoarthritis have never heard of viscosupplementation as a medical treatment. Instead, their physicians recommend the more standard treatments of oral medications and surgery. Providers may even be less likely to encourage viscosupplementation among patients because of its unproven efficacy, unaffordable cost, and the potential for multiple injection procedures. Lack of awareness and educational efforts hinders wider utilization and further market expansion.

Single Injection Viscosupplementation Market

The single-injection viscosupplementation market is likely to experience significant growth in the future. This potential growth is due to several reasons:

• The single-injection method is more convenient for both physicians and patients.
• There is an increasing requirement for outpatient surgeries, with a focus on same-day surgical care, which includes preventive and diagnostic surgeries.
• Companies are making efforts to create single-injection products for osteoarthritis, thus increasing product launches.

Increasing attention toward the delivery of effective treatments for osteoarthritis patients aligns with the general approach to single-injection product development and is contributing to expected market growth of viscosupplementation during the entire forecast period.

Knee osteoarthritis viscosupplementation market

Knee osteoarthritis has become the segment with the most significant dominance in the viscosupplementation market. The market growth has primarily been due to increasing knee osteoarthritis cases and the number of geriatric population, who are more prone to this disease. Due to the aging process, knee osteoarthritis is one of the most common causes of knee-related ailments. This is because the water content of cartilage declines with age, reducing its ability to absorb shock and act as a cushion, making the elderly more vulnerable to knee-related diseases. The high prevalence of knee osteoarthritis and its association with age reinforce this patient population as the most dominant in the viscosupplementation market.

The Orthopedic Clinics/Ambulatory Surgical Centers Market

The orthopedic clinics and ambulatory surgical centers market is experiencing steady annual growth. This trend reflects the growing demand for specialized orthopedic services and the adoption of outpatient surgical procedures. Patients increasingly prefer these facilities for convenience, efficient services, and reduced hospitalization time. Moreover, advancements in medical technology and the emphasis on providing comprehensive orthopedic care contribute to the sustained expansion of this market. With healthcare constantly evolving towards more patient-centric models, the expansion of orthopedic clinics and ambulatory surgical centers reflects this changing landscape of orthopedic healthcare services.

United States Viscosupplementation Market

The U.S. viscosupplementation market is steadily increasing, driven by the ever-increasing prevalence of osteoarthritis among an aging population. Viscosupplementation, which involves the injection of hyaluronic acid into joints, is becoming a preferred treatment for knee osteoarthritis as a non-invasive alternative to surgery. The market benefits from rising demand for minimally invasive procedures and advancements in hyaluronic acid formulations that offer longer-lasting relief. Additionally, increasing healthcare access and awareness about non-surgical treatment options contribute to the market's expansion. The U.S. is one of the most vital markets for viscosupplementation, with research and innovation supporting it. Recently, in November 2022, Anika Therapeutics, Inc. received the primary endpoint in Phase III Study for Cingal. This product provides long-term pain relief from knee OA. The firm focuses on getting the FDA approval of the Cingal product and its launch in the U.S. This positive test resulted in the company enhancing its R&D activities and also getting a competitive edge over the competitors.

France Viscosupplementation Market

The French viscosupplementation market is experiencing a steady growth, and the major reason behind this growth is the increasing incidence of osteoarthritis, especially among the elderly population. Hyaluronic acid injections to treat knee osteoarthritis by restoring the lubrication in the joint are becoming one of the popular treatments in France. The country's advanced healthcare system, high awareness of non-surgical treatment alternatives, and an aging demographic support the market. In addition, the focus of France on bettering access to healthcare and outcomes encourages the adoption of viscosupplementation. The growing preference for minimally invasive procedures over surgery and the development of innovative hyaluronic acid formulations are key factors driving the market.

China Viscosupplementation Market

The growth of the market for viscosupplementation in China is driven by diversified factors such as demographics and incidence, prevalence, of diseases, macroeconomic environments, and geopolitical issues. Fluctuations in market trends may be the consequences of sudden changes in one or more of these and changes in clinical practice as they translate into changing a diagnosis or treatment given to patients as part of a broader efforts to improve medical practice itself. The U.S. market for viscosupplementation is growing with a rising number of patients with osteoarthritis looking for a non-surgical solution. According to the CDC, around 34.5 million Americans experience osteoarthritis each year; it is characterized by lower levels of hyaluronic acid causing pain and stiffness. Interest in this non-surgical option is increasing in light of fears about surgical procedures and costs of treatment. Ongoing innovations in hyaluronic acid treatments, formulated by leading companies to treat knee pain quickly, continue driving the market. Scientists are also studying various ways of slowing down the development of knee pain diseases during this growth cycle.

Saudi Arabia Viscosupplementation Market

Saudi Arabia viscosupplementation market is growing with the growing population of the aged and joint health awareness for better treatments of osteoarthritis. Hyaluronic acid injection-based non-invasive therapy for osteoarthritis of knee is increasingly becoming a popular method, providing comfort and efficient movement of joints. High-end health facilities and high health care cost in the country facilitate acceptance of this type of treatments. Emphasis on surgery avoidance and provision of alternate treatment alternatives are also growing in Saudi Arabia, impacting the market. Other such factors and innovations in healthcare and governmental efforts boost the growth of this market in Saudi Arabia.

Key Player in the viscosupplementation market

The main players in the viscosupplementation market are Anika Therapeutics Inc., Zimmer Biomet, Smith & Nephew PLC, F.Hoffmann-La Roche Ltd, Sanofi, Chugai Pharmaceutical Co., Lifecore Biomedical, and LG Life Sciences Ltd.

• December 2023 Bioventus Inc., a leader in active healing innovations globally, reported that it has entered into a nationwide agreement with Aetna™ Medicare Advantage plans.
• For example, the Population Reference Bureau estimates that the population aged 65 and older is projected to increase from 58 million in 2022 to 82 million in 2050. Thus, the share of the 65 and older age group in the total population is projected to increase from 17% in 2022 to 23% in 2050. This demographic trend is tantamount to an increasing pool of individuals at risk for developing osteoarthritis, a common degenerative condition of the joints associated with aging.

Product – Injection Market have been covered from 3 viewpoints

1.    Single
2.    Three
3.    Five

Application – Market have been covered from 5 viewpoints

1.    Knee
2.    Hip
3.    Hand/Wrist
4.    Ankle/Foot
5.    Others

End User – Market have been covered from 2 viewpoints

1.    Hospitals
2.    Orthopedic clinics/Ambulatory Surgical Centers

Region – Market have been covered from 25 Countries viewpoints

1.    North America

1.1    United States
1.2    Canada

2.    Europe

2.1    France
2.2    Germany
2.3    Italy
2.4    Spain
2.5    United Kingdom
2.6    Belgium
2.7    Netherlands
2.8    Turkey

3.    Asia Pacific

3.1    China
3.2    Japan
3.3    India
3.4    South Korea
3.5    Thailand
3.6    Malaysia
3.7    Indonesia
3.8    Australia
3.9    New Zealand

4.    Latin America

4.1    Brazil
4.2    Mexico
4.3    Argentina

5.    Middle East & Africa

5.1    Saudi Arabia
5.2    United Arab Emirates
5.3    South Africa

Company Analysis

•    Overview 
•    Recent Development
•    Revenue

Companies Covered

1.    Anika Therapeutics Inc
2.    Zimmer Biomet
3.    Smith & Nephew PLC
4.    F.Hoffmann-La Roche Ltd
5.    Sanofi
6.    Chugai Pharmaceutical Co
7.    Lifecore Biomedical
8.    LG Life Sciences Ltd

Report Details: